Literature DB >> 3006002

Evaluation of prostatic cancer histology and grade distribution: experience with the Colorado Central Cancer Registry.

B Brooks, G J Miller.   

Abstract

Although well-defined grading schemes for prostatic adenocarcinoma have been developed, they are not yet universally accepted by practicing surgical pathologists. The complexity of these schemes often leads surgical pathologists to develop their own modified Broders scheme. This study compared the grade distribution as obtained by a community of surgical pathologists with that obtained using the National Prostatic Cancer Project (NPCP) and Gleason grading schemes. In 1978, 308 cases of prostate cancer were reported to the Colorado Central Cancer Registry (CCCR) from the Denver Standard Metropolitan Statistical Area. Two hundred eighteen of these cases were regraded. The grade distribution as reported by the CCCR revealed a predominance of low-grade tumors (grade I-41%, grade II-28%, grade III-17%, grade IV-3%). Regrading of these same cases revealed a shift to higher grades (NPCP: grade I-14%, grade II-11%, grade III-37%, grade IV-29%; Gleason: pattern scores less than 6-30%, score 6-24%, score 7-12%, score 8-11%, score 9-10%, score 10-4%). Twenty-one cases of histologic variants which were not originally diagnosed were also noted (six mucinous, 12 ductal, two endometroioid, one squamous). There were 18 cases in which no evidence of carcinoma was confirmed. These results suggest that there is a tendency to underestimate grade and potentially malignant behavior when well-defined prostatic cancer grading schemes are not applied.

Entities:  

Mesh:

Year:  1986        PMID: 3006002     DOI: 10.1002/pros.2990080205

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Connective tissue protein in the prostate gland.

Authors:  T Nakada; Y Kubota
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

2.  LEF1 identifies androgen-independent epithelium in the developing prostate.

Authors:  Xinyu Wu; Garrett Daniels; Ellen Shapiro; Kun Xu; Hongying Huang; Yirong Li; Susan Logan; M Alba Greco; Yi Peng; Marie E Monaco; Jonathan Melamed; Herbert Lepor; Irina Grishina; Peng Lee
Journal:  Mol Endocrinol       Date:  2011-04-28

3.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.